Elutiaformerly Known As Aziyo Biologicsspecializes In Drug Eluting Biomatrix Technologiesthe Company Is Dedicated To Developing And Commercializing Biologic Products That Enhance The Compatibility Of Medical Devices With Patientselutia Aims To Improve Patient Outcomes And Reduce Post Surgical Complicationswhich Can Affect Recovery And Medical Costs The Companyae S Primary Focus Is On Creating Drug Eluting Biomatrix Products That Deliver Drugs Locallynotable Offerings Include The Cangaroo Envelopewhich Stabilizes Implantable Cardiac Devicesand Eluprothe First Fda Cleared Antibiotic Eluting Bioenvelope For Protecting Patients With Devices Like Pacemakers And Neurostimulatorselutia Is Also Preparing To Launch Cangaroo Rmwhich Will Provide Sustained Antibiotic Delivery Elutia Has Established Partnerships With Organizations Such As Southern Strategic Sourcing Partners To Enhance Access To Its Products In Various Medical Settingsthe Company Continues To Growcelebrating Significant Milestones In 2024Including Fda Approval For Elupro And Plans To Expand Into The Neurostimulator Market For Pain Management
